Harmony Biosciences Surpasses Q1 2025 Expectations with Strong Financial Results and Strategic Growth
Harmony Biosciences Holdings Inc. reported strong Q1 2025 financials, exceeding market expectations with $184.7 million in revenue and $0.78 EPS, solidifying its position in the pharmaceutical sector.
- Harmony Biosciences Holdings Inc
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read